Geron stock jnj
3 May 2019 After Geron's (GERN) stock price experienced a meteoric rise and equally spectacular JNJ chose not to continue with Imetelstat, not Janssen. 27 Sep 2018 J&J's Janssen Biotech unit attributed the decision to a “strategic portfolio evaluation and prioritization of assets.” GP: Scientist in lab and 13 Mar 2020 Geron Corporation GERN incurred a loss of 15 cents per share in fourth-quarter 2019, Johnson & Johnson (JNJ): Free Stock Analysis Report Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. 13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX.
13 Mar 2020 Geron Corporation GERN incurred a loss of 15 cents per share in fourth-quarter 2019, Johnson & Johnson (JNJ): Free Stock Analysis Report
More. Copy link to Tweet; Embed Tweet. #imetelstat Geron's imetelstat has so much potential ! $gernpic.twitter.com/CdjerLipfZ. 1 reply 2 retweets 12 likes. Reply. 18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly 27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including 27 Sep 2018 Geron's imetelstat story already has had more twists than a Hitchcock film, and today that knocked Geron out of the billion-dollar biotech club as shares Geron's chief executive, John Scarlett, chalked up J&J's decision to a 7 Feb 2018 Mid last year, the stock took a hit as investors became wary about the company's partnership with Johnson & Johnson (NYSE:JNJ) regarding its 3 days ago Real-time trade and investing ideas on Geron Corporation GERN from the largest community of traders and investors.
27 Sep 2018 Geron's imetelstat story already has had more twists than a Hitchcock film, and today that knocked Geron out of the billion-dollar biotech club as shares Geron's chief executive, John Scarlett, chalked up J&J's decision to a
13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX. Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug 18 Jul 2018 In his comments during JNJ's quarterly earnings conference call, Mr. interest in Geron shares is 52.7 million shares according to Nasdaq's More. Copy link to Tweet; Embed Tweet. #imetelstat Geron's imetelstat has so much potential ! $gernpic.twitter.com/CdjerLipfZ. 1 reply 2 retweets 12 likes. Reply. 18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly 27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including 27 Sep 2018 Geron's imetelstat story already has had more twists than a Hitchcock film, and today that knocked Geron out of the billion-dollar biotech club as shares Geron's chief executive, John Scarlett, chalked up J&J's decision to a
Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX. Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug 18 Jul 2018 In his comments during JNJ's quarterly earnings conference call, Mr. interest in Geron shares is 52.7 million shares according to Nasdaq's More. Copy link to Tweet; Embed Tweet. #imetelstat Geron's imetelstat has so much potential ! $gernpic.twitter.com/CdjerLipfZ. 1 reply 2 retweets 12 likes. Reply.
18 Jul 2018 In his comments during JNJ's quarterly earnings conference call, Mr. interest in Geron shares is 52.7 million shares according to Nasdaq's
18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly 27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including
7 Feb 2018 Mid last year, the stock took a hit as investors became wary about the company's partnership with Johnson & Johnson (NYSE:JNJ) regarding its